Eyepoint Pharmaceuticals, Inc.
Clinical trials sponsored by Eyepoint Pharmaceuticals, Inc., explained in plain language.
-
New eye drug could mean fewer shots for Diabetes-Related vision loss
Disease control Recruiting nowThis study tests a new medicine, EYP-1901, given as an eye injection to people with diabetic macular edema (DME), a condition that causes blurry vision in people with diabetes. The goal is to see if EYP-1901 works as well as the standard treatment (aflibercept) but with fewer inj…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New eye drug could cut injection frequency for Diabetes-Related vision loss
Disease control Recruiting nowThis phase 3 trial tests EYP-1901, a new eye injection, against the standard treatment aflibercept for diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The study will enroll 240 participants and compare how well each drug improves vision …
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC